GLP-1 receptor agonists: hormone biology and clinical effects

Glucagon-like peptide-1 (GLP-1) is a 30-amino-acid peptide hormone produced by L cells in the distal small intestine and colon. It is released in response to nutrients in the gut — most strongly to carbohydrates and fats — within minutes of eating.

GLP-1 belongs to the incretin family: hormones from the gut that amplify the pancreas's insulin response to a meal. The 'incretin effect' — the observation that oral glucose produces a much larger insulin response than the same amount of intravenous glucose — was identified in the 1960s and explained by gut hormones in the 1980s.

GLP-1's physiological actions, mediated by the GLP-1 receptor (GLP-1R) on multiple cell types, include:

• Glucose-dependent insulin secretion from pancreatic beta cells. Insulin release is amplified by GLP-1R activation, but only when blood glucose is elevated — the action stops when glucose normalizes.
• Suppression of glucagon secretion from pancreatic alpha cells when glucose is high.
• Delayed gastric emptying — food leaves the stomach more slowly, blunting post-meal glucose peaks.
• Reduced appetite — central effects in hypothalamic and brainstem regions that regulate hunger.

Native GLP-1 has a half-life of about 1–2 minutes in circulation. It is degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves off the first two amino acids and inactivates the molecule. This short half-life made native GLP-1 useless as a drug; the engineering challenge for receptor-agonist drugs was to make a molecule that activates the same receptor but resists DPP-4 and renal clearance for long enough to be dosed weekly or daily.

The GLP-1 receptor is a G-protein-coupled receptor (GPCR) with seven transmembrane helices, the same structural family as roughly 35% of all approved drug targets. It is expressed on:

• Pancreatic beta cells (insulin secretion).
• Pancreatic alpha cells (glucagon suppression).
• Stomach and gut smooth muscle (gastric emptying).
• Cardiac and vascular cells (cardiovascular effects).
• Brain (appetite regulation in the hypothalamus and area postrema; reward signaling).
• Kidney (sodium handling, with effects on blood pressure).
• Liver, adipose tissue, and immune cells (anti-inflammatory and metabolic effects).

GLP-1R signaling activates the Gαs subunit, which raises intracellular cAMP. In beta cells, the cAMP rise potentiates the calcium-dependent insulin-release machinery — but only when calcium is already elevated, which requires high glucose. This is the structural reason GLP-1 agonists rarely cause hypoglycemia: the insulin amplification depends on the same glucose signal that normally triggers insulin.

The wide distribution of the receptor explains the wide range of effects observed with GLP-1 agonists. It also explains the side-effect profile: receptors in the stomach drive nausea and gastroparesis; receptors in the brain drive both appetite suppression (intended) and the early nausea (a side effect that usually tolerates with dose titration).

Native GLP-1 lasts minutes. Clinical agonists last hours to a week. The engineering strategies that achieved this are illustrative of broader peptide-drug development.

Exenatide (Byetta, twice daily; Bydureon, weekly). The first GLP-1 agonist approved in 2005. Exenatide is exendin-4, a peptide from Gila monster venom. It is naturally resistant to DPP-4 (its first amino acids do not match DPP-4's preferred cleavage site) and has a longer half-life than native GLP-1 (~2.4 hours).

Liraglutide (Victoza for diabetes, 2010; Saxenda for obesity, 2014). A modified GLP-1 with a fatty acid (C16) attached at one position. The fatty acid binds reversibly to serum albumin, extending half-life to ~13 hours. Daily dosing.

Semaglutide (Ozempic for diabetes, 2017; Wegovy for obesity, 2021; Rybelsus oral for diabetes, 2019). A further-modified GLP-1 with two amino-acid substitutions (resisting DPP-4 cleavage) and a longer C18 fatty acid with a spacer that binds albumin much more tightly. Half-life ~7 days, enabling weekly subcutaneous dosing.

Tirzepatide (Mounjaro for diabetes, 2022; Zepbound for obesity, 2023). A dual agonist that activates both GLP-1R and GIP receptor (another incretin). The combined activation appears to produce more weight loss than GLP-1 agonism alone. Weekly subcutaneous dosing.

Retatrutide (in trials at writing). A triple agonist (GLP-1R + GIP R + glucagon receptor) with reported weight-loss effects exceeding tirzepatide in trial data.

The trajectory: each successive generation extends duration, increases potency, or expands the receptor profile. The underlying chemistry — peptide synthesis at scale, modifications for stability — depends on a specialized manufacturing supply chain centered on a few firms (Novo Nordisk, Eli Lilly, plus contract manufacturers).

GLP-1 agonists were developed for type 2 diabetes, but the weight-loss effect emerged as more clinically significant for many patients.

The weight-loss mechanism has multiple components:

• Reduced food intake. Central appetite-suppressing effects in the hypothalamus and area postrema reduce hunger and food intake. Patients describe reduced appetite, earlier satiety, and reduced food-craving intensity.
• Delayed gastric emptying. Slower stomach emptying produces earlier satiety mechanically — patients feel full longer after smaller meals.
• Reduced reward signaling from food. Receptors in brain reward pathways appear to reduce the hedonic component of eating — the food still tastes the same, but the drive to eat for pleasure rather than hunger is reduced.

Quantitatively, in clinical trials at full therapeutic doses over 16–17 months:

• Semaglutide 2.4 mg weekly (STEP-1, STEP-3 trials): mean weight loss of about 15% of body weight vs. about 2% on placebo.
• Tirzepatide 15 mg weekly (SURMOUNT-1 trial): mean weight loss of about 21% vs. about 3% on placebo.
• Retatrutide 12 mg weekly (Phase 2 trial): mean weight loss of about 24% vs. about 2% on placebo.

These magnitudes are substantially larger than the 3–8% typical of earlier weight-loss medications. The clinical relevance: 15–20% weight loss approaches the range of bariatric surgery outcomes, though by a non-surgical mechanism that requires continued treatment to maintain.

When treatment stops, weight typically regains over the following 12 months, often to most of the pre-treatment level. The drugs do not produce a metabolic 'reset' — they alter intake and emptying for as long as the drug is present.

Several large outcome trials have established effects of GLP-1 agonists beyond glycemic control and weight.

Cardiovascular outcomes.

• LEADER (liraglutide, 2016) and SUSTAIN-6 (semaglutide, 2016): reductions in major adverse cardiovascular events (MACE — composite of cardiovascular death, non-fatal MI, non-fatal stroke) in patients with type 2 diabetes and high cardiovascular risk. Effect size: roughly 13–26% relative reduction in MACE depending on trial.
• SELECT (semaglutide, 2023): a cardiovascular outcomes trial in patients with obesity and prior cardiovascular disease without diabetes. Showed roughly 20% MACE reduction over a median 40 months. This was the first cardiovascular benefit demonstrated for a weight-loss agent in non-diabetic patients.

Kidney outcomes.

• FLOW (semaglutide, 2024): reduction in major kidney disease events in patients with type 2 diabetes and chronic kidney disease.

Other reported associations.

• Reduced rates of obstructive sleep apnea, MASH (metabolic dysfunction-associated steatohepatitis), and certain other obesity-associated conditions.
• Observational signals for reduced rates of substance-use disorders and possibly some neurodegenerative conditions — currently active areas of research with limited randomized data.

The structural lesson: GLP-1R is expressed on many tissues, and GLP-1 agonists have systemic effects. Some of these are mediated through weight loss; others appear to be direct receptor effects. Distinguishing 'effect of weight loss' from 'direct receptor effect' is an active research question that randomized trials are gradually addressing.

GLP-1 agonist side effects derive from the same wide receptor distribution that produces the intended effects.

Common side effects (all dose-dependent, most tolerate with titration):

• Gastrointestinal: nausea (the most common), vomiting, diarrhea, constipation, gastroparesis (delayed gastric emptying becoming clinically symptomatic in some patients). The GI side effects often diminish over weeks of dose titration but can persist or recur at higher doses.
• Injection-site reactions: redness, itching, swelling at the subcutaneous injection site.
• Reduced appetite (an intended effect) can become problematic if it leads to inadequate caloric or protein intake, with risk of muscle loss along with fat loss.
• Gallbladder events: rapid weight loss raises gallstone formation; GLP-1 agonist trials have reported increased rates of cholelithiasis and cholecystitis.

Rare but important:

• Pancreatitis: imbalanced rates in some trials; current consensus is that the absolute risk increment is small but real.
• Medullary thyroid cancer: GLP-1R is expressed on rodent C-cells, where GLP-1 agonists caused C-cell tumors in long-term rodent studies. Human C-cells appear to have lower GLP-1R expression and the human risk has not been observed in trials, but the drugs are contraindicated in patients with personal or family history of medullary thyroid carcinoma.
• Aspiration risk under anesthesia: gastroparesis can leave food in the stomach long after fasting, raising aspiration risk during anesthesia. Surgical guidelines have evolved to require longer fasting or evaluation of gastric contents before procedures.

The overall tolerability profile in trials is acceptable for the indicated populations; in routine use, dose titration and counseling on protein/caloric intake materially affect outcomes.

Peptide drugs are made by solid-phase peptide synthesis (SPPS) or fermentation, both of which require specialized facilities and skilled operators. The post-2021 demand surge for GLP-1 agonists — particularly semaglutide and tirzepatide — outpaced manufacturing capacity, producing multi-year shortages of injectable products and constrained launches of the obesity indications in many markets.

The structural constraints:

• Active pharmaceutical ingredient (API) supply. Peptide synthesis at the scale of millions of weekly doses requires large bioreactor and chromatography capacity, plus specialty solvents and reagents in tight supply.
• Fill-finish capacity. Sterile injectable manufacturing — filling pre-filled pens or vials under aseptic conditions — has limited global capacity, much of it pre-committed under existing contracts.
• Cold chain. Most peptide injectables require refrigerated distribution.
• Regulatory. Each manufacturing site for each indication and each market requires specific regulatory authorization; capacity is not fully fungible.

The response from manufacturers has been billion-dollar capacity expansions at both API and fill-finish, taking 2–4 years to come online. New entrants (oral small-molecule GLP-1 agonists, off-patent peptide synthesis as patents expire) are expected to expand the pipeline, but in the short run the supply constraint has shaped access — by price, by indication eligibility, by geographic market — more than the underlying clinical demand alone would.

The pricing and access debate is therefore unusual: a class of drugs with very large clinical effect, large eligible population, sustained dosing requirements, and constrained supply — a combination that has put GLP-1 agonists at the center of pharmaceutical policy discussions in many countries.

Three structural points for the cursus.

• Hormone biology has a wide reach. A single hormone-receptor axis (GLP-1 / GLP-1R) produces effects on glucose, gastric emptying, appetite, cardiovascular risk, kidney function, and several other systems — because the receptor is broadly expressed. A drug that engages such a receptor inherits the breadth.
• Peptide engineering follows a clear playbook. Modify the peptide to resist degradation; attach a fatty acid for albumin binding; adjust the sequence to tune receptor selectivity. Successive generations of agonists move along this playbook with successively longer durations and broader effects.
• Effect size and durability are linked. GLP-1 agonists produce substantial effects only while the drug is being given; stopping the treatment typically reverses much of the weight effect. This shapes clinical-use patterns (chronic, indefinite) and the policy debates around access.

The next lesson moves out of specific therapies and into the structural framework that governs how new therapies are evaluated: the clinical trial system, the regulatory approval process, and what the actual standards for 'effective' and 'safe' look like in practice.